Sygnature Discovery

What Sygnature Discovery does

Sygnature Discovery is a UK-headquartered, privately held contract research organization providing integrated preclinical drug discovery services to global biotechnology and pharmaceutical clients. The company delivers end-to-end programs from target identification through clinical candidate nomination, spanning target ID/validation, hit identification (HIT SYNERGY), hit-to-lead, lead optimization, and preclinical development. Its scientific stack combines computational chemistry, AI-enabled design, structural biology (X-ray crystallography, cryo-EM, NMR), medicinal and high-throughput chemistry, bioscience, DMPK, in vivo pharmacology, and formulation. Co-located multidisciplinary teams of 700+ scientists (70% PhDs, from 50+ countries) operate across UK sites in Nottingham, Alderley Park, Macclesfield, and Glasgow, and Canadian sites in Montreal and Lévis.

The business operates as a professional services CRO, generating revenue through project-based contracts, FTE allocations, milestone payments, and standalone scientific service engagements. GTM is sales-led and enterprise-focused, with no intermediaries or self-serve channels; distribution relies on direct field sales, inside sales for inbound qualification, and customer referrals reinforced by a 90%+ retention rate. Sygnature differentiates on proprietary platforms — SygDesign (informatics), CHARMED (PROTAC/targeted protein degradation), STRATA (17M+ compound virtual library), FMO-SP (quantum SBDD), and AI4Lit (literature analytics) — and integrates third-party AI tools (Iktos Makya, BullFrog AI, DaltonTx, AlphaFold). Since 2011 the company has delivered 61 pre-clinical and 38 clinical compounds, with one contributed therapy (relacorilant) receiving FDA approval as Lifyorli for ovarian cancer. Ownership rests with Five Arrows Principal Investments (Rothschild & Co), which invested in June 2021, and the company has executed a deliberate inorganic growth strategy with three acquisitions since 2020.

Name

Sygnature Discovery

Legal name

Sygnature Discovery Limited

Website

https://sygnaturediscovery.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sygnature Discovery is a UK-headquartered, privately held contract research organization delivering integrated preclinical drug discovery from target identification to clinical candidate nomination for global biotech and pharmaceutical clients, with 700+ scientists across the UK and Canada.

Ownership category

akta.pro rank

Product category

Drug Discovery Contract Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Contract research organization
• Drug discovery services
• Preclinical drug development
• Medicinal chemistry services
• Pharmaceutical research

Headquarters

HQ city

Nottingham

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Integrated Drug Discovery Services: Full-service contract research organization providing end-to-end drug discovery programs from target identification through pre-clinical development. Revenue generated through project-based contracts, FTE allocation, milestone payments, and standalone service engagements.
2. Standalone Scientific Services: Modular services including CADD, protein science, bioscience, chemistry, DMPK, in vivo pharmacology, and formulation offered as standalone engagements or integrated with full programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Sygnature Discovery is a contract research organization providing integrated drug discovery services from target identification through to pre-clinical candidate nomination. The company delivers end-to-end programs as well as standalone scientific services spanning medicinal chemistry, computational chemistry and AI-driven drug design, bioscience, protein science and structural biology, DMPK, in vivo pharmacology, and formulation for biotech and pharmaceutical clients.

Product overview

Sygnature Discovery is a world-leading integrated drug discovery contract research organization (CRO) offering end-to-end preclinical drug discovery services from target identification to clinical candidate nomination. The core offering is Integrated Drug Discovery programs delivered through 700+ co-located multidisciplinary scientists across UK and North American sites. The service portfolio comprises Target Identification & Validation, HIT SYNERGY (Hit Identification), Hit-to-Lead, Lead Optimization, and Preclinical Development, supported by specialized Scientific Solutions including Computer Aided Drug Design (CADD) with AI capabilities, Bioinformatics, Virtual Screening, Structure-Based Drug Design, Protein Science & Structural Biology, Bioscience, Chemistry, DMPK, In Vivo Pharmacology, and Form & Formulation. Proprietary tools include SygDesign for informatics. The company integrates third-party AI platforms (DaltonTx, BullFrog AI, Iktos Makya) alongside its own capabilities. Modalities covered include small molecules, peptides, targeted protein degradation, ADCs, and biologics across therapeutic areas including oncology, immunology, neuroscience, and metabolic diseases. Since 2011, the company has delivered 61 pre-clinical compounds and 38 clinical compounds.

Differentiator

Problem solved

Functional benefit

Brands

• SygDesign: Proprietary informatics platform for compound design and data tracking
• HIT SYNERGY
• CHARMED

Products and services

• Integrated Drug Discovery Fully integrated drug discovery programs delivered by 700+ co-located multidisciplinary scientists from target identification through to candidate selection and pre-clinical development, with no internal drug pipeline.
• Target Identification & Validation AI-driven target identification and validation platform combining literature analysis, expert insights, and rigorous lab validation to guide targets through robust evaluation into hit discovery, for biotech and pharma clients.
• HIT SYNERGY (Hit Identification) Integrated hit identification service combining virtual screening, high-throughput screening, fragment screening, and affinity selection mass spectrometry to deliver high-quality, structurally diverse hits.
• Hit-to-Lead Hit assessment and optimization services including high-throughput chemistry, in silico profiling, core hopping, screening cascades, and in vitro ADME assays to deliver high-quality leads for biotech and pharma clients.
• Lead Optimization Multidisciplinary lead optimization combining medicinal chemistry, DMPK, safety assessment, and in vivo pharmacology to transform early leads into clinical-quality candidates with optimized potency, selectivity, and ADMET properties.
• Computer Aided Drug Design (CADD) AI-powered computational drug design service combining structure-based and ligand-based design, predictive modelling, virtual screening, ADMET prediction, bioinformatics, and secure collaborative data access.
• Bioinformatics End-to-end bioinformatics solutions supporting target identification, biomarker discovery, and translational decision-making through integrated analysis of transcriptomics, sequencing, and multi-omics data.
• Virtual Screening In silico virtual high-throughput screening using OpenEye Orion platform, enabling screening of billions of compounds in hours through structure-based and ligand-based techniques with curated and proprietary compound libraries.
• Structure-Based Drug Design Quantum-level structure-based drug design service integrating Fragment Molecular Orbital analysis, Molecular Dynamics simulations, and Relative Binding Free Energy calculations for precision compound optimization.
• Protein Science & Structural Biology High-quality protein production, purification, and characterization services including X-ray crystallography, cryo-EM, and macromolecular NMR for structural biology insights.
• Bioscience Tailored bioscience solutions including cell line generation, assay development, electrophysiology, high-throughput screening, and primary cells and tissues for target validation and lead optimization.
• Chemistry Global chemistry expertise spanning medicinal chemistry, synthetic chemistry, process and scale-up chemistry, NMR spectroscopy, separation sciences, high-throughput chemistry, and direct-to-biology approaches.
• Drug Metabolism and Pharmacokinetics (DMPK) Integrated DMPK solutions including in vitro ADME profiling, in vivo PK/PD studies, bioanalysis, biotransformation, and PK/PD modelling to support candidate nomination and IND applications.
• In Vivo Pharmacology High-quality in vivo pharmacology services across CNS/pain, metabolic disease, inflammation/immunology, and oncology models with pharmacokinetics, biomarkers, and exploratory toxicology capabilities.
• Form & Formulation Early clinical formulation, solid form analysis, salt and co-crystal screening, polymorph screening, and pre-clinical formulation services to support drug development and regulatory readiness.
• Modalities Drug Discovery (Small Molecules, Peptides, ADCs, Biologics, Targeted Protein Degradation) Modality-agnostic drug discovery spanning small molecules, peptides, targeted protein degradation (PROTACs, molecular glues), antibody-drug conjugates (ADCs), and biologics for biotech and pharma clients.

Quantifiable outcome

• 61 novel pre-clinical compounds delivered since 2011, with 38 progressed to clinical trials, 2 approved or under regulatory review
• +3 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature9 records

Partnerships

Six partnerships are on record, tiered core.

• DaltonTxcoreTechnology or Integration · 10 June 2026Strategic collaboration with DaltonTx to incorporate their AI-powered Dalton drug discovery platform into Sygnature's computational and medicinal chemistry toolkit. Sygnature is conducting a retrospective evaluation of a legacy oncology programme involving a small-molecule clinical candidate in Phase I to assess platform benefits. The partnership includes SygDesign, BullFrog AI, and Iktos as existing integrated technologies.
• IktoscoreTechnology or Integration3-year collaboration for deployment of Iktos' AI technology Makya for generative AI in de novo molecular design and lead optimization. Iktos Makya is integrated into Sygnature's computational drug design workflows.
• BullFrog AIcoreTechnology or IntegrationIntegration of BullFrog AI's analysis platform into Sygnature's AI-enabled drug discovery capabilities, supporting target identification and validation workflows.
• OpenEyecoreTechnology or IntegrationLicensed use of OpenEye's Orion platform for ultra-high throughput virtual screening, molecular docking, and RBFE calculations using Non-Equilibrium Switching methodology.
• Pathios TherapeuticscoreStrategic or Co-development PartnerStrategic partnership to discover novel GPR65 modulators for autoimmune disease treatment, applying integrated drug discovery capabilities.
• UBE CorporationcoreStrategic or Co-development PartnerCollaboration with UBE Corporation to identify potent SHP2 degrader compounds using Sygnature's CHARMED PROTAC platform.

Scale indicators11 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Eurofins Discovery: Eurofins Discovery is the drug discovery arm of Eurofins Scientific, offering medicinal chemistry, ADME/DMPK, and pharmacology services globally. While broader and more fragmented than Sygnature, it competes for similar biotech and pharma discovery outsourcing work and operates from European and US sites.
• WuXi AppTec: WuXi AppTec is one of the largest global CRO/CDMOs with a broad WuXi Discovery services platform (chemistry, biology, DMPK, in vivo) that competes with Sygnature for biotech and pharma discovery programmes. Geopolitical headwinds have begun redirecting Western sponsor programmes toward European-based CROs, putting Sygnature in a competitive position to gain share.
• Labcorp Drug Development: Labcorp Drug Development (formerly Covance) is a global CRO offering early discovery, pre-clinical, clinical and central lab services to pharma and biotech. Its Central Laboratory Services and Early Development divisions overlap directly with Sygnature's integrated drug discovery and DMPK offerings, making it a broad incumbent competitor.
• Charles River Laboratories: Charles River operates one of the largest global preclinical CRO footprints spanning discovery, safety assessment, and manufacturing services. Its Discovery & Safety Assessment segment directly overlaps Sygnature's integrated drug discovery and in vivo pharmacology offerings, and it competes head-to-head for large-pharma strategic partnership mandates.

Direct peers

• Curia (formerly AMRI): Curia is a global CDMO/CRO offering drug discovery, medicinal chemistry and pre-clinical development services alongside manufacturing. Its Discovery and Development segment competes with Sygnature for integrated discovery mandates from US-headquartered biotech and pharma sponsors.
• Domainex: Domainex is a UK-based integrated drug discovery CRO providing medicinal chemistry, biology, ADME and protein expression services to biotech and pharma sponsors. As a smaller UK-headquartered peer, it competes with Sygnature for early-stage biotech programmes and shares the same sovereign and regulatory operating environment.
• Concept Life Sciences: Concept Life Sciences is a UK-headquartered discovery CRO offering medicinal chemistry, in vitro ADME, structural biology and pharmacology services. It operates from a smaller scale than Sygnature but competes in similar enterprise biotech and pharma programmes, often as a specialist sub-segment participant.
• Pharmaron: Pharmaron is a China-headquartered, globally integrated CRO offering drug discovery, DMPK, pharmacology, and chemistry services with co-located multidisciplinary teams across US, UK and China sites. It competes with Sygnature for biotech and pharma discovery outsourcing mandates and operates at a similar integrated-services scale.
• Selvita: Selvita is a Kraków-based integrated drug discovery CRO providing medicinal chemistry, in vitro/in vivo pharmacology, DMPK and ADME services to biotech and pharma clients. It is one of the largest European-headquartered integrated discovery CROs and targets the same early-stage-to-clinical sponsor segment as Sygnature.
• Evotec SE: Evotec is a Hamburg-based integrated drug discovery CRO operating a comparable end-to-end platform (Target ID through pre-clinical) with similar co-located multidisciplinary teams. It is one of Sygnature's closest direct competitors in the small-molecule and biologics discovery space, sharing enterprise pharma and biotech sponsor lists and modality coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCWUzxh2tPSL0Oer35E8tWow
• LinkedInlinkedin.com/company/sygnature-discovery/?viewAsMember=true
• Xx.com/SygnatureDiscov

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sygnature Discovery